Shots:
- VectorBuilder & Lir have collaborated to develop AAV capsids, leveraging VectorBuilder’s DeepCap platform & expertise & Lir’s nAAVigator AI platform
- Lir will use its platform & lab-in-the-loop workflow to enhance capsids discovered through DeepCap, targeting higher productivity, full-capsid yield, quality, robustness, lower doses, & greater tissue specificity with reduced off-target delivery & immune recognition
- Companies will evaluate multiple lead capsids across selected therapeutic applications using iterative AI-guided engineering, experimental validation & manufacturing assessment, with resulting data supporting further optimization of VectorBuilder’s capsid portfolio
Ref: PRnewswire | Image: VectorBuilder & Lir | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
